跳至主要内容
临床试验/NCT00002084
NCT00002084已完成不适用

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Glaxo Wellcome89 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
89

研究概览

简要总结

To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have:
  • HIV infection with CD4 counts = or > 100 cells/mm
  • Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
  • History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.

排除标准

  • Co-existing Condition:
  • Patients with the following symptoms and conditions are excluded:
  • Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
  • Concurrent Medication:
  • Systemic antiherpes medication.
  • Interferon.
  • Patients with the following prior conditions are excluded:
  • History of hypersensitivity to acyclovir.

研究者

发起方
Glaxo Wellcome
申办方类型
Industry

研究点 (89)

Loading locations...

相似试验

A Comparative Trial of Valacyclovir Hydrochloride (... | 临床试验